Jian Wang

Jian Wang’s practice focuses on cross-border mergers and acquisitions, capital markets transactions, corporate finance, investments and public company compliance matters.

Mr. Wang’s experience includes advising:

Going-Private Acquisitions

• a buyer consortium lead by Sizhen Wang on its US$126 million going-private acquisition of Genetron Holdigns Limited
• the special committee of the board of directors of O2Micro International Limited on the US$146 million going-private acquisition of O2Micro
• the independent board committee of Wanda Sports Group Company on the acquisition of the remaining 28% stake in Wanda Sports Group for US$105 million
• Charles Chao on his US$2.6 billion going-private acquisition of Sina Corporation
• a buyer group comprising of Guilan Jiang, her extended family members and Qijun Huang on their going-private acquisition of Fuling Global Inc.
• 58.com Inc. on its US$8.7 billion going-private acquisition by an investor consortium that included Warbus Pincus Asia LLC, General Atlantic Singapore Fund Pte. Ltd., Ocean Link Partners Limited and Jinbo Yao
• Leo Ou Chen on his US$130 million going-private acquisition of the remaining stake in Jumei International Holding Limited through a two-step merger
• the special committee of the board of directors of Changyou.com Limited on the US$579 million going-private acquisition of Changyou.com by Sohu.com Limited
• a buyer consortium led by Baofang Jin on its US$362 million going-private acquisition of JA Solar Holdings Co., Ltd.

Capital Markets

• Nomura Securities International, Inc. as sole underwriter on the US$200 million IPO of Generation Asia I Acquisition Limited
• Sinopec Group Overseas Development (2018) Limited on its multiple Rule 144A/Regu-lation S offerings of U.S. dollar-denominated senior notes
• 9F Inc. on its US$85 million IPO of American depositary shares (ADS) and listing on Nasdaq, and on its US$60 million PIPE transaction
• Qifu Technology, Inc. on its US$200 million pre-IPO financing, US$51 million IPO of ADS and listing on Nasdaq, and its US$96 million follow-on offering of ADS by its shareholders
• China Petroleum & Chemical Corporation on its voluntary delisting of ADS from NYSE and Rule 12h-6 deregistration under U.S. securities laws
• CASI Pharmaceuticals, Inc. on its redomiciliation from Delaware to the Cayman Islands and the related registered exchange offering of ordinary shares
• Huaneng Power International Inc. on its voluntary delisting of ADS from the NYSE and Rule 12h-6 deregistration under U.S. securities laws
• U.S.-listed companies, including CASI Pharmaceuticals, Inc. and 9F Inc., as well as China Petroleum & Chemical Corporation, Huaneng Power International Inc. and JA Solar Holdings Co., Ltd. on their regulatory compliance and preparation of filings under Securities Exchange Act of 1934